Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results forOREX
5.29
-0.07 (-1.31%)
Jul 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 5.27 - 5.37
52 week 4.59 - 7.84
Open 5.31
Vol / Avg. 1.77M/3.14M
Mkt cap 615.37M
P/E     -
Div/yield     -
EPS -0.82
Shares 116.33M
Beta 2.68
Inst. own 88%
Aug 7, 2014
Orexigen Therapeutics Inc at Piper Jaffray Heartland Summit - 10:15am GMT-4 - Add to calendar
Aug 4, 2014
Q2 2014 Orexigen Therapeutics, Inc. Earnings Release (Estimated) Add to calendar
Jul 8, 2014
Orexigen Therapeutics Inc at Piper Jaffray Catalyst Symposium
Jun 27, 2014
Orexigen Therapeutics, Inc. Annual Shareholder Meeting
Jun 23, 2014
Orexigen Therapeutics, Inc. Annual Shareholder Meeting (Estimated)
Jun 18, 2014
Orexigen Therapeutics Inc at Wells Fargo Healthcare Conference
Jun 11, 2014
Orexigen Therapeutics Inc Receives Three Month Extension of FDA NB32 Review Call - Webcast
May 14, 2014
Orexigen Therapeutics, Inc. at Bank of America Merrill Lynch Health Care Conference - Webcast
May 8, 2014
Q1 2014 Orexigen Therapeutics, Inc. Earnings Conference Call - Webcast
May 8, 2014
Q1 2014 Orexigen Therapeutics, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -2905.25% -2265.78%
Operating margin -2701.75% -2251.98%
EBITD margin - -2249.24%
Return on average assets -59.05% -48.65%
Return on average equity -318.49% -132.40%
Employees 50 -
CDP Score - -

Address

Suite 200, 3344 N. Torrey Pines Court
LA JOLLA, CA 92037
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.

Officers and directors

Eckard Weber M.D. Independent Chairman of the Board
Age: 63
Bio & Compensation  - Reuters
Michael A. Narachi President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Joseph P. Hagan Acting Chief Financial Officer, Treasurer, Chief Business Officer
Age: 44
Bio & Compensation  - Reuters
Heather D. Turner Senior Vice President, General Counsel, Secretary
Age: 39
Bio & Compensation  - Reuters
Preston Klassen M.D. Head of Global Contrave Program, Senior Vice President - Product Development
Age: 44
Bio & Compensation  - Reuters
Mark D. Booth Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 49
Bio & Compensation  - Reuters
Wendy L. Dixon Ph.D Independent Director
Age: 58
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 72
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 49
Bio & Compensation  - Reuters